DEVA HOLDING |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 73 TRY | +1.53% |
|
-1.22% | -3.38% |
| 12/02 | Tod's rises 17% on L Catterton bids to help owner's delisting plan | RE |
| 2023 | Deva Holding A.S. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
| Sales 2021 | 2.33B 71.64M 5.97B | Sales 2022 | 4.48B 138M 11.48B | Capitalization | 13.84B 426M 35.48B |
|---|---|---|---|---|---|
| Net income 2021 | 1.17B 35.97M 3B | Net income 2022 | 1.36B 41.81M 3.49B | EV / Sales 2021 | 2.65 x |
| Net Debt 2021 | 423M 13.01M 1.08B | Net Debt 2022 | 2.06B 63.42M 5.29B | EV / Sales 2022 | 3.55 x |
| P/E ratio 2021 |
4.91
x | P/E ratio 2022 |
10.2
x | Employees | 2,931 |
| Yield 2021 |
0.52% | Yield 2022 |
0.22% | Free-Float | 17.79% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.53% | ||
| 1 week | -1.22% | ||
| Current month | +2.17% | ||
| 1 month | +1.46% | ||
| 3 months | -11.84% | ||
| 6 months | -15.07% | ||
| Current year | -3.38% |
1 week
71.65
76.05
1 month
67.0576.05
Current year
67.0591.20
1 year
36.04101.00
3 years
21.50101.00
5 years
4.25101.00
10 years
1.73101.00
| Managers | Title | Age | Since |
|---|---|---|---|
Philipp Haas
CEO | Chief Executive Officer | - | 14/06/14 |
Mesut Çetin
DFI | Director of Finance/CFO | 45 | 14/08/14 |
Altug Uysal
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Philipp Haas
CEO | Chief Executive Officer | - | 14/06/14 |
Mesut Çetin
DFI | Director of Finance/CFO | 45 | 14/08/14 |
Aysecik Haas
BRD | Director/Board Member | - | 22/13/22 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 73 | +1.53% | 448,656 |
| 25/24/25 | 71.9 | -1.24% | 593,638 |
| 24/24/24 | 72.8 | -1.49% | 467,207 |
| 22/24/22 | 73.9 | 0.00% | 812,382 |
| 19/24/19 | 73.9 | +0.68% | 531,690 |
Delayed Quote Borsa Istanbul, April 26, 2024 at 08:38 pm IST
More quotes
Deva Holding AS is a Turkey-based pharmaceutical company that is primarily engaged in the production and marketing of finished pharmaceutical products, pharmaceutical ingredients and veterinary products, as well as animal health products, among others. The Company has four production facilities in Turkey. Its production facilities include the Tokapi, Cerezkoy I, Cerezkoy II and Kartepe production plants. The Companyâs product portfolio comprises 73 drugs, which are available on the market in 177 various forms. It offers products, such as Azitro, Alemax, Cefax, Inhibace, Imatis, Hydrea, Kardozin, Kristapen, Magcar, Magnesie Calcinee, Nostil, Oceral, Remidon, Prolixin and Quet, among others. The Company has two subsidiaries, namely Vetaa Veteriner ve Tarim Ilaclari A.S. and Deva Holding NZ Ltd.
Sector
Pharmaceuticals
Calendar
03/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -3.38% | 450M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- DEVA Stock
